Today, the long-term weight management indication of Eli Lilly Mufengda (Tenpo Peptide Injection) has been approved by the National Medical Products Administration. Mufengda is the first and currently the only approved glucose dependent insulinotropic polypeptide (GIP)/glucagon like peptide-1 (GLP-1) receptor agonist, and also the first innovative drug approved by Eli Lilly in the field of obesity treatment in China.